ISSN: 1134-8046
e-ISSN: 2254-6189

Indexada en:

Busqueda avanzada

Year 2022 / Volume 29 / Supplement 1

Abstract PDF

HTML

Cannabinoids Article

Medical cannabis and cancer: benefits for cancer pain and other related symptoms

Rev. Soc. Esp. Dolor. 2022; 29(13): 14-19 / DOI: 10.20986/resed.2022.4026/2022

Manuel Herrero

ABSTRACT

Cannabis has the potential to modulate some of the most common symptoms of cancer, either from the tumour itself or from its treatments. However, the paucity of scientific evidence for its effectiveness and the historical stigma causes a problem to clinicians for choosing it as a therapeutic option for their patients. This review reflects the influence of medical cannabis on the most common and debilitating symptoms in cancer, including pain, chemotherapy-induced nausea and vomiting, chemotherapy-induced peripheral neuropathy, and anorexia and loss of appetite. Additionaly we do a review of the medical cannabis as an anticancer agent.

RESUMEN

El cannabis tiene el potencial de modular algunos de los síntomas más prevalentes en el cáncer, ya sean derivados del propio tumor o de los tratamientos antitumorales. Sin embargo, la escasez de evidencia científica sobre su eficacia y el estigma histórico ocasiona un problema para que los profesionales médicos puedan elegirlo como una opción terapéutica para sus pacientes. Esta revisión refleja la influencia del cannabis medicinal en los síntomas más prevalentes y debilitantes en cáncer, incluyendo el dolor, las náuseas y los vómitos inducidos por quimioterapia, la neuropatía periférica inducida por quimioterapia, y la anorexia y la pérdida de apetito. Asimismo, se repasa la evidencia actual del cannabis como agente anticanceroso.

Complete Article

Nuevo comentario

Security code:

Comentarios

No comments in this article

Bibliografía

1. Chung M, Kim HK, Abdi S. Update on cannabis and cannabinoids for cancer pain. Curr Opin Anaesthesiol. 2020;33(6):825-31.

DOI: 10.1097/ACO.0000000000000934

2. Saadeh CE, Rustem DR. Medical Marijuana Use in a Community Cancer Center. J Oncol Pract. 2018;14(9):e566-e578.

DOI: 10.1200/JOP.18.00057

3. Martell K, Fairchild A, LeGerrier B, Sinha R, Baker S, Liu H, et al. Rates of cannabis use in patients with cancer. Curr Oncol. 2018;25(3):219-25.

DOI: 10.3747/co.25.3983

4. Braun IM, Wright A, Peteet J, Meyer FL, Yuppa DP, Bolcic-Jankovic D, et al. Medical Oncologists' Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. J Clin Oncol. 2018;36(19):1957-62.

DOI: 10.1200/JCO.2017.76.1221

5. Kleckner AS, Kleckner IR, Kamen CS, Tejani MA, Janelsins MC, Morrow GR, et al. Opportunities for cannabis in supportive care in cancer. Ther Adv Med Oncol. 2019;11:1758835919866362.

DOI: 10.1177/1758835919866362

6. Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. 2017;42(9):1752-65.

DOI: 10.1038/npp.2017.51

7. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016;17(6):739-44.

DOI: 10.1016/j.jpain.2016.03.002

8. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167-79.

DOI: 10.1016/j.jpainsymman.2009.06.008

9. The National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.

Guerrero AV, Quang P, Dekker N, Jordan RC, Schmidt BL. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett. 2008;433(2):77-81.

DOI: 10.1016/j.neulet.2007.12.053

11. Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37-43.

DOI: 10.1016/j.ejim.2018.01.023

12. Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11(3):119-33.

DOI: 10.1177/2049463717710042

13. Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, et al. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. 2017;6(Suppl 2):S215-S222.

DOI: 10.21037/apm.2017.08.05

14. Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325-45.

DOI: 10.1200/JCO.2016.68.5206

15. Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, et al. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer. 2015;23(9):2833-40.

DOI: 10.1007/s00520-015-2809-3

16. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 2002;137(5):589-96.

DOI: 10.1038/sj.bjp.0704829

17. Malik Z, Baik D, Schey R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep. 2015;17(2):429.

DOI: 10.1007/s11894-015-0429-1

18. Lever IJ, Malcangio M. CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. Br J Pharmacol. 2002;135(1):21-4.

DOI: 10.1038/sj.bjp.0704506

19. Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-63.

DOI: 10.1111/j.1365-2125.2010.03743.x

20. Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. J Med Toxicol. 2017;13(1):71-87.

DOI: 10.1007/s13181-016-0595-z

21. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-97.

DOI: 10.1200/JCO.20.01296

22. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.

DOI: 10.1016/j.jep.2006.02.001

23. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461-70.

DOI: 10.1016/j.pain.2014.09.020

24. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain. 2005;118(1-2):23-34.

DOI: 10.1016/j.pain.2005.07.008

25. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol. 2007;152(5):765-77.

DOI: 10.1038/sj.bjp.0707333

26. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014;171(3):636-45.

DOI: 10.1111/bph.12439

27. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47(1):166-73.

DOI: 10.1016/j.jpainsymman.2013.02.018

28. Waissengrin B, Mirelman D, Pelles S, Bukstein F, Blumenthal DT, Wolf I, et al. Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. Ther Adv Med Oncol. 2021;13:1758835921990203.

DOI: 10.1177/1758835921990203

29. Støving RK, Andries A, Brixen K, Flyvbjerg A, Hørder K, Frystyk J. Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. J Psychiatr Res. 2009;43(7):671-9.

DOI: 10.1016/j.jpsychires.2008.09.007

30. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136(4):550-7.

DOI: 10.1038/sj.bjp.0704767

31. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567-73.

DOI: 10.1200/JCO.2002.20.2.567

32. Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, Oñate-Ocaña LF, Zatarain-Barrón ZL, Barrón F, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26(9):3029-38.

DOI: 10.1007/s00520-018-4154-9

33. Bar-Sela G, Zalman D, Semenysty V, Ballan E. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. Integr Cancer Ther. 2019;18:1534735419881498.

DOI: 10.1177/1534735419881498

34. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;55(3):597-602.

DOI: 10.1093/jnci/55.3.597

35. Foroughi M, Hendson G, Sargent MA, Steinbok P. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas--possible role of Cannabis inhalation. Childs Nerv Syst. 2011;27(4):671-9.

DOI: 10.1007/s00381-011-1410-4

36. Kenyon J, Liu W, Dalgleish A. Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. Anticancer Res. 2018;38(10):5831-5.

DOI: 10.21873/anticanres.12924

37. Likar R, Koestenberger M, Stultschnig M, Nahler G. Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature. Anticancer Res. 2019;39(10):5797-801.

DOI: 10.21873/anticanres.13783

38. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203.

DOI: 10.1038/sj.bjc.6603236

39. Twelves C, Sabel M, Checketts D, Miller S, Tayo B, Jove M, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. 2021;124(8):1379-87.

DOI: 10.1038/s41416-021-01259-3

Instrucciones para citar

Herrero M. Medical cannabis and cancer: benefits for cancer pain and other related symptoms. Rev Soc Esp Dolor 2022; 29(13): 14-19 / DOI: 1020986/resed20224026/2022

Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 9197 veces.
Este artículo ha sido descargado 1 veces.

Estadísticas de Dimensions

Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 14/09/2022

Publicado: 28/10/2022

Este artículo aun no tiene valoraciones.

Reader rating:

Rate this article:

Send by e-mail

Gestión de Cookies	Nombre	Tipo de Cookie	Función
Google	NID, PREF	Persistente	Personalizar los anuncios que se muestran en los servicios de Google.
Google Analytics	__utma, __utmb, __utmc, __utmz	Persistente	Conocer de forma anónima, nº de visitantes, procedencia, páginas visitadas, etc.